{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/201067","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02076386","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"DOL-ART","allocation":"","arm_groups":[{"arm_group_label":"Dolutegravir","arm_group_description":"Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.","arm_type":""}],"assignment":"","brief_summary":"DOL-ART is a multi-center, prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. The primary study objective is a descriptive characterization of the frequency of therapeutic monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine daily practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of dolutegravir, due to death, withdrawal of consent, lost to follow-up).","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A prospective, non-interventional study of the use of dolutegravir as part of combination antiretroviral therapy in routine daily practice in Germany","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:22:01","criteria":"Inclusion Criteria: - Documented HIV infection - Age ≥ 18 years - Decision for the first initiation of dolutegravir as part of an ART by the attending physician irrespective of inclusion in this observational study - Prior to the start of this study, the patient must have been receiving a dolutegravir-containing ART for at least 4 weeks Exclusion Criteria: - Discontinuation of dolutegravir as part of an ART prior to the start of the study documentation - Participation in a clinical trial during this study - Participation in a clinical trial or compassionate use program with dolutegravir being or having been part of the investigational medication","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"411","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"d2aadf56-2759-561e-b50e-719c4e2294bf","internal":{"content":null,"contentDigest":"2991903951f242750458ae8c37f612ce","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Documented HIV infection - Age ≥ 18 years - Decision for the first initiation of dolutegravir as part of an ART by the attending physician irrespective of inclusion in this observational study - Prior to the start of this study, the patient must have been receiving a dolutegravir-containing ART for at least 4 weeks Exclusion Criteria: - Discontinuation of dolutegravir as part of an ART prior to the start of the study documentation - Participation in a clinical trial during this study - Participation in a clinical trial or compassionate use program with dolutegravir being or having been part of the investigational medication","interventions":[{"arm_group_label":"Dolutegravir","intervention_description":"Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.","intervention_name":"Dolutegravir","intervention_type":"Drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"06/20/2017 00:00:00","links":[],"locations":[{"City":"Berlin","Latitude":"52.4950243","CountryDisplay":"Germany","Longitude":"13.3147792","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10707","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1362105","CountryDisplay":"Germany","Longitude":"11.572893","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80331","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1381386","CountryDisplay":"Germany","Longitude":"11.6033512","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"81675","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5147455","CountryDisplay":"Germany","Longitude":"13.43856","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10243","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5341936","CountryDisplay":"Germany","Longitude":"13.4230065","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10405","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bochum","Latitude":"51.4813394","CountryDisplay":"Germany","Longitude":"7.2168733","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"44787","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hannover","Latitude":"52.3749839","CountryDisplay":"Germany","Longitude":"9.7388153","Name":"GSK Investigational Site","StateDisplay":"Niedersachsen","PostalCode":"30159","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Stuttgart","Latitude":"48.7716577","CountryDisplay":"Germany","Longitude":"9.1494571","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"70197","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5064936","CountryDisplay":"Germany","Longitude":"13.2856413","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"14057","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mainz","Latitude":"49.9990416","CountryDisplay":"Germany","Longitude":"8.2746565","Name":"GSK Investigational Site","StateDisplay":"Rheinland-Pfalz","PostalCode":"55116","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Freiburg","Latitude":"48.0044582","CountryDisplay":"Germany","Longitude":"7.8374651","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"79106","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chemnitz","Latitude":"50.8365233","CountryDisplay":"Germany","Longitude":"12.9239317","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"09111","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hamburg","Latitude":"53.5580847","CountryDisplay":"Germany","Longitude":"10.011979","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20099","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hamburg","Latitude":"53.5510846","CountryDisplay":"Germany","Longitude":"9.9936819","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Frankfurt am Main","Latitude":"50.1109221","CountryDisplay":"Germany","Longitude":"8.6821267","Name":"GSK Investigational Site","StateDisplay":"Hessen","PostalCode":"60590","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Frankfurt","Latitude":"50.1100897","CountryDisplay":"Germany","Longitude":"8.6822492","Name":"GSK Investigational Site","StateDisplay":"Hessen","PostalCode":"60311","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dortmund","Latitude":"51.5081979","CountryDisplay":"Germany","Longitude":"7.4416173","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"44137","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5496772","CountryDisplay":"Germany","Longitude":"13.3643415","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"13347","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1340355","CountryDisplay":"Germany","Longitude":"11.5571732","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80336","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mannheim","Latitude":"49.4861656","CountryDisplay":"Germany","Longitude":"8.4702616","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"68161","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1582691","CountryDisplay":"Germany","Longitude":"11.5786882","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80801","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Koblenz","Latitude":"50.3481531","CountryDisplay":"Germany","Longitude":"7.5616813","Name":"GSK Investigational Site","StateDisplay":"Rheinland-Pfalz","PostalCode":"56073","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tuebingen","Latitude":"48.5392481","CountryDisplay":"Germany","Longitude":"9.0615313","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"72076","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Koeln","Latitude":"50.9346454","CountryDisplay":"Germany","Longitude":"6.9331365","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"50674","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1443383","CountryDisplay":"Germany","Longitude":"11.5548236","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80335","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hamburg","Latitude":"53.5688101","CountryDisplay":"Germany","Longitude":"9.9819779","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20146","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Muenster","Latitude":"51.9630088","CountryDisplay":"Germany","Longitude":"7.6267552","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"48143","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Koeln","Latitude":"50.934707","CountryDisplay":"Germany","Longitude":"6.9759562","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"50679","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Duesseldorf","Latitude":"51.2357381","CountryDisplay":"Germany","Longitude":"6.8091727","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"40237","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Osnabrueck","Latitude":"52.3073196","CountryDisplay":"Germany","Longitude":"8.026685","Name":"GSK Investigational Site","StateDisplay":"Niedersachsen","PostalCode":"49090","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Koeln","Latitude":"50.9485731","CountryDisplay":"Germany","Longitude":"6.9629492","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"50668","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Magdeburg","Latitude":"52.0884882","CountryDisplay":"Germany","Longitude":"11.6320016","Name":"GSK Investigational Site","StateDisplay":"Sachsen-Anhalt","PostalCode":"39120","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.4972347","CountryDisplay":"Germany","Longitude":"13.3429021","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"10777","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Aachen","Latitude":"50.7780476","CountryDisplay":"Germany","Longitude":"6.0887682","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"52062","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.493094","CountryDisplay":"Germany","Longitude":"13.3968551","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10961","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fuerth","Latitude":"49.4723395","CountryDisplay":"Germany","Longitude":"10.9930876","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"90762","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Weimar","Latitude":"50.9936113","CountryDisplay":"Germany","Longitude":"11.3203362","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"99427","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.5517268","CountryDisplay":"Germany","Longitude":"13.4123013","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"10439","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:33:18","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Other","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Prospective"},"official_title":"A prospective, non-interventional study of the use of dolutegravir as part of combination antiretroviral therapy in routine daily practice in Germany (DOL-ART)","org_study_id":"201067","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"No","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"","primary_compl_date":"06/20/2017 00:00:00","primary_outcomes":[{"outcome_description":"Descriptive characterization of the frequency of therapeutic monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine daily practice in Germany.","outcome_measure":"Frequency of therapeutic monitoring measures in HIV-infected patients","outcome_time_frame":"up to 3 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Type of the therapeutic monitoring measures","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"To evaluate the frequency and type of serious adverse events and drug-related adverse events in patients treated with dolutegravir.","outcome_measure":"Number of participants with Serious Adverse Events and drug-related adverse events as a measure of safety and tolerability","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"Defined as viral load < 50 copies/ml","outcome_measure":"Efficacy","outcome_time_frame":"from start of dolutegravir up to 3 years","outcome_safety_issue":null},{"outcome_description":"To characterise resistance profile in case of virological failure","outcome_measure":"Resistance profile","outcome_time_frame":"from start of dolutegravir up to 3 years","outcome_safety_issue":null},{"outcome_description":"To evaluate the change in patient satisfaction relative to baseline in patients treated with dolutegravir","outcome_measure":"Patient satisfaction","outcome_time_frame":"Up to 3 years from baseline","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reasons for selecting dolutegravir-containing ART","outcome_time_frame":"Baseline","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reasons for discontinuing dolutegravir-containing ART","outcome_time_frame":"Up to 3 years after baseline","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"03/04/2014 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"201067"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}